Selected 5-HT1D Agonists/MAO Inhibitors Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, your body may not process your migraine headache medicine properly.

What might happen:

The blood levels of your migraine headache medicine may increase and cause harmful effects.

What you should do about this interaction:

Contact your healthcare professionals (e.g. doctor or pharmacist) as soon as possible about taking these two medicines together. They may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

View Reference
  • 1.Maxalt (rizatriptan) US prescribing information. Merck & Co., Inc. October, 2019.
  • 2.Imigran Tablets, Injection, and Nasal Spray (sumatriptan) Australian prescribing information. GlaxoSmithKline February 11, 2002.
  • 3.Imigran Radis (sumaptriptan) UK summary of product characteristics. GlaxoSmithKline UK June 8, 2004.
  • 4.Imitrex Tablets (sumatriptan) US prescribing information. GlaxoSmithKline December 14, 2017.
  • 5.Imigran Nasal Spray (sumatriptan) UK summary of product characteristics. GlaxoSmithKline UK July 8, 2004.
  • 6.Imitrex Nasal Spray (sumatriptan) US prescribing information. GlaxoSmithKline December 14, 2017.
  • 7.Imigran Injection (sumatriptan) UK summary of product characteristics. GlaxoSmithKline UK September 19, 2003.
  • 8.Imitrex Injection (sumatriptan) US prescribing information. GlaxoSmithKline December 14, 2017.
  • 9.Imitrex (sumatriptan) CA prescribing information. GlaxoSmithKline Inc. September 22, 2011.
  • 10.Zomig (zolmitriptan) US prescribing information. AstraZeneca Pharmaceuticals LP September, 2012.
  • 11.Zomig (zolmitriptan) UK summary of product characteristics. Zeneca Limited March, 1997.
  • 12.Relpax (eletriptan hydrobromide) US prescribing information. Pfizer Inc. March, 2020.
  • 13.Frova (frovatriptan) US prescribing information. Endo Pharmaceuticals August, 2018.
  • 14.Eldepryl (selegiline) US prescribing information. Somerset Pharmaceuticals February, 1997.
  • 15.Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 2007 Nov;152(6):946-51.
  • 16.Peter C, Hongwan D, Kupfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 2000 Jun;56(3):247-50.
  • 17.Surmaitis RM, Nappe TM, Cook MD. Serotonin syndrome associated with therapeutic metaxalone in a patient with cirrhosis. Am J Emerg Med 2016 Feb;34(2):346.e5-6.
  • 18.Skelaxin (metaxalone) US prescribing information. Pfizer Laboratories Div Pfizer Inc. January, 2024.
  • 19.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.
Full Drug Information

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.